Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 208-214

  Carlsson, Jörgen ^a   Shen, L ^b   Xiang, J ^b   Xu, J ^b   Wei, Q ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; EGFR; HER2; HER3; Lymph nodes; Metastasis; Prostate; Radionuclides; Receptor expression; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIMARY TUMOR; PROSTATE CANCER; SCORING SYSTEM; STAINING; UPREGULATION;

EID: 84869071866     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.996     Document Type: Article

References (51)

1. Sharkey RM and Goldenberg DM: Cancer radioimmunotherapy. Immunotherapy 3: 349-370, 2011.
2. Carlsson J: Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors. Tumour Biol 33: 653-659, 2012.
3. Carlsson J: EGFR-family expression and implications for targeted radionuclide therapy. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G and Carlsson J (eds). Springer Verlag, pp 25-58, 2008.
4. Houssami N, Macaskill P, Balleine RL, Bilous M and Pegram MD: HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat 129: 659-674, 2011.
5. Pecorino L (ed): Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics. Oxford University Press, Oxford, 2005.
6. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
7. Bublil EM and Yarden Y: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19: 124-134, 2007.
8. Morgillo F, Bareschino MA, Bianco R, Tortora G and Ciardiello F: Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75: 788-799, 2007.
9. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
10. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.
11. Nahta R and Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643, 2007.
12. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402, 2007.
13. Jathal MK, Chen L, Mudryj M and Ghosh PM: Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem 11: 131-149, 2011.
14. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H and Carlsson J: EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 15: 1193-1201, 2008.
15. Wei Q, Chen L, Sheng L, Nordgren H, Wester K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31: 493-499, 2007.
16. Ekberg T, Nestor M, Engström M, Nordgren H, Wester K, Carlsson J and Anniko M: Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26: 1177-1185, 2005.
17. Wei Q, Shui Y, Zheng S, Wester K, Nordgren H, Nygren P, Glimelius B and Carlsson J: EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep 25: 3-11, 2011.
18. Gleason DF; The Veteran's Administration Cooperative Urologic Research Group: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Tannenbaum M (ed). Lea and Febiger, Philadelphia, pp171-198, 1977.
19. Gleason DF: Histology grading of prostate cancer: a perspective. Hum Path 23: 273-279, 1992.
20. Held-Warmkessel J (ed): Contemporary Issues in Prostate Cancer: A Nursing Perspective. Jones & Bartlett Learning, pp107-125, 2006.
21. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G and van de Vijver M: Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16: 173-182, 2003.
22. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ and Fidler IJ: Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9: 1200-1210, 2003.
23. Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C and Bologna M: Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 93: 964-975, 2005.
24. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J and Cordon-Cardo C: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1: 545-550, 1995.
25. Shah RB, Ghosh D and Elder JT: Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66: 1437-1444, 2006.
26. Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C and Bologna M: Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncol Rep 18: 503-511, 2007.
27. Hernes E, Fossá SD, Berner A, Otnes B and Nesland JM: Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 90: 449-454, 2004.
28. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B and Edwards J: Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 205: 522-529, 2005.
29. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr and Reventos J: Prognostic value of immunohistochemical expression of the c-erb B-2 oncoprotein in metastasic prostate cancer. Int J Cancer 84: 421-425, 1999.
30. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K and Sudilovsky D: HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 116: 234-239, 2001.
31. Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R and LaSalle JM: Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J 7: 395-403, 2001.
32. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, Nogue M, Domenech M and Fabregat X: Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 10: 4742-4745, 2004.
33. Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D, Sabatier L and Chauveinc L: Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer 90: 443-448, 2004.
34. Myers RB, Srivastava S, Oelschlager DK and Grizzle WE: Expression of p160erb B-3 and p185erb B-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86: 1140-1145, 1994.
35. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY and Lin SH: Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203: 688-695, 2004.
36. Gusterson B, Cowley G, Smith JA and Ozanne B: Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 8: 649-658, 1984.
37. Damjanov I, Mildner B and Knowles BB: Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 55: 588-592, 1986.
38. Dittadi R, Gion M, Pagan V, Brazzale A, Del Maschio O, Bargossi A, Busetto A and Bruscagnin G: Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer 64: 741-744, 1991.
39. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM and Ullrich A: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45: 457-461, 1990.
40. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
41. Gutierrez C and Schiff R: HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135: 55-62, 2011.
42. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW and Scher HI: Efficacy and safety of single-agent pertuzumab (rhu MAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25: 675-681, 2007.
43. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, et al: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257-262, 2007.
44. Solit DB and Rosen N: Targeting HER2 in prostate cancer: where to next? J Clin Oncol 25: 241-243, 2007.
45. Gallick GE, Corn PG, Zurita AJ and Lin SH: Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4: 107-119, 2012.
46. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, et al: Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17: 6218-6228, 2011.
47. Stigbrand T, Carlsson J and Adams GP: Developmental trends in targeted radionuclide therapy-biological aspects. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G and Carlsson J (eds). Springer Verlag, pp 387-397, 2008.
48. Frejd YF: Novel alternative scaffolds and their potential use for tumor targeted radionuclide therapy. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G and Carlsson J (eds). Springer Verlag, pp 89-116, 2008.
49. Govindan SV and Goldenberg DM: New antibody conjugates in cancer therapy. Scientific World Journal 10: 2070-2089, 2010.
50. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157, 2005.
51. Gedda L, Fondell A, Lundqvist H, Park JW and Edwards K: Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. J Nucl Med 53: 480-487, 2012.